Compare SNY & CSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNY | CSX |
|---|---|---|
| Founded | 1994 | 1978 |
| Country | France | United States |
| Employees | N/A | 23000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Railroads |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.5B | 94.5B |
| IPO Year | 2001 | 1994 |
| Metric | SNY | CSX |
|---|---|---|
| Price | $45.42 | $51.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 20 |
| Target Price | ★ $58.00 | $43.05 |
| AVG Volume (30 Days) | 2.9M | ★ 10.3M |
| Earning Date | 04-23-2026 | 04-22-2026 |
| Dividend Yield | ★ 3.47% | 1.25% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.97 |
| Revenue | N/A | ★ $10,636,000,000.00 |
| Revenue This Year | $3.49 | $4.58 |
| Revenue Next Year | $6.10 | $4.89 |
| P/E Ratio | ★ $6.14 | $53.10 |
| Revenue Growth | N/A | ★ 17.64 |
| 52 Week Low | $40.89 | $31.80 |
| 52 Week High | $52.68 | $53.60 |
| Indicator | SNY | CSX |
|---|---|---|
| Relative Strength Index (RSI) | 61.92 | 60.30 |
| Support Level | $45.71 | $49.57 |
| Resistance Level | $48.66 | $51.64 |
| Average True Range (ATR) | 0.51 | 0.77 |
| MACD | 0.22 | 0.05 |
| Stochastic Oscillator | 88.17 | 77.80 |
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Operating in the Eastern United States, Class I railroad CSX generated revenue of nearly $14 billion in 2025. On its more than 21,000 miles of track, CSX hauls shipments of coal (16% of consolidated revenue), chemicals (17%), intermodal containers (16%), automotive cargo (7%), and a diverse mix of other bulk and industrial merchandise.